180 Life Sciences’ Woody Sets Out Vision For Repurposing Anti-TNF Biologics
CEO Expands On Recent Announcement Of Collaboration With Celltrion
After 180 Life Sciences recently struck a deal with Korea’s Celltrion to support its work in repurposing off-patent biologics, CEO Jim Woody speaks to Generics Bulletin about what the collaboration means for the company and its next steps.
